Alkermes Plc (ALKS) Position Lowered by Aviva PLC
Aviva PLC lessened its position in shares of Alkermes Plc (NASDAQ:ALKS) by 22.3% in the 4th quarter, HoldingsChannel reports. The fund owned 57,473 shares of the company’s stock after selling 16,519 shares during the period. Aviva PLC’s holdings in Alkermes were worth $1,696,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Bank of Montreal Can boosted its stake in shares of Alkermes by 7.9% in the 3rd quarter. Bank of Montreal Can now owns 18,992 shares of the company’s stock worth $807,000 after buying an additional 1,391 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Alkermes by 767.3% in the 3rd quarter. Russell Investments Group Ltd. now owns 54,217 shares of the company’s stock worth $2,303,000 after buying an additional 47,966 shares during the last quarter. Wells Fargo & Company MN boosted its stake in shares of Alkermes by 14.7% in the 3rd quarter. Wells Fargo & Company MN now owns 342,481 shares of the company’s stock worth $14,534,000 after buying an additional 43,862 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. boosted its stake in shares of Alkermes by 79.1% in the 3rd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 147,889 shares of the company’s stock worth $6,276,000 after buying an additional 65,330 shares during the last quarter. Finally, SG Americas Securities LLC boosted its stake in shares of Alkermes by 722.9% in the 3rd quarter. SG Americas Securities LLC now owns 21,814 shares of the company’s stock worth $926,000 after buying an additional 19,163 shares during the last quarter. Hedge funds and other institutional investors own 97.83% of the company’s stock.
A number of equities analysts have recently weighed in on the company. Zacks Investment Research upgraded Alkermes from a “hold” rating to a “buy” rating and set a $36.00 target price on the stock in a research note on Tuesday, January 29th. TheStreet raised shares of Alkermes from a “d” rating to a “c-” rating in a report on Tuesday, February 19th. Wolfe Research began coverage on shares of Alkermes in a report on Friday, December 14th. They issued an “underperform” rating on the stock. ValuEngine cut shares of Alkermes from a “hold” rating to a “sell” rating in a report on Wednesday, January 2nd. Finally, Goldman Sachs Group cut shares of Alkermes from a “neutral” rating to a “sell” rating and lowered their price target for the stock from $49.00 to $26.00 in a report on Tuesday, December 18th. Four equities research analysts have rated the stock with a sell rating, six have given a hold rating and six have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $44.15.
Alkermes (NASDAQ:ALKS) last issued its earnings results on Thursday, February 14th. The company reported $0.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.39. Alkermes had a negative net margin of 12.73% and a negative return on equity of 0.49%. The business had revenue of $316.00 million for the quarter, compared to analysts’ expectations of $255.71 million. During the same quarter in the previous year, the firm posted $0.31 EPS. The business’s revenue for the quarter was up 14.9% compared to the same quarter last year. As a group, sell-side analysts expect that Alkermes Plc will post -0.41 EPS for the current year.
In other news, Director Paul J. Mitchell sold 1,000 shares of the business’s stock in a transaction on Friday, January 4th. The shares were sold at an average price of $30.00, for a total transaction of $30,000.00. Following the completion of the transaction, the director now directly owns 8,000 shares in the company, valued at approximately $240,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Michael J. Landine sold 25,000 shares of the business’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $33.05, for a total transaction of $826,250.00. Following the transaction, the senior vice president now owns 210,122 shares of the company’s stock, valued at $6,944,532.10. The disclosure for this sale can be found here. Insiders have sold a total of 158,000 shares of company stock worth $5,244,560 in the last three months. Insiders own 5.51% of the company’s stock.
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability.
Featured Article: How does the Federal Reserve determine interest rates?
Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes Plc (NASDAQ:ALKS).
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.